MAZE
Maze Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.41B
P/E Ratio
—
EPS
$-3.05
Beta
—
52W High
$53.65
52W Low
$6.80
50-Day MA
$44.10
200-Day MA
$30.75
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.53
PEG Ratio
—
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-140.50M |
| Operating Margin | 0.00% |
| Return on Equity | -47.50% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.20 |
| Price-to-Book | 4.02 |
| Price-to-Sales (TTM) | 501.65 |
| EV/Revenue | 537.07 |
| EV/EBITDA | 6.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $49.71M |
| Float | $27.70M |
| % Insiders | 1.82% |
| % Institutions | 103.11% |
Analyst Ratings
Consensus ($64.82 target)
1
Strong Buy11
BuyData last updated: 4/8/2026